ClinicalTrials.gg
CompletedNCT01112306Updated Mar 30, 2025Results posted

ACT-293987 in Pulmonary Arterial Hypertension

A Phase 3 interventional study of ACT-293987 in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 157 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
709
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.

Enrollment
2nd of 12
709 · median 67
Started
2010
the only one that year
Phase 3
6 of 12
1 open now
Registered
2nd of 12
by date
Lead sponsor
9 of 12
Actelion

Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 2nd largest by enrollment, is the only one that started in 2010, is one of 6 in phase 3, and was the 2nd registered.

Pulmonary Arterial Hypertension

699 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About selexipag

selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing selexipag in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Open-label
  • PAH
  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who participated to the double-blind study AC-065A302 and either had a morbidity event or had completed the study as scheduled per protocol.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Patients who have started receiving prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) since the last study drug intake in AC-065A302/GRIPHON.
  • Severe hepatic impairment ( C).
  • Females who are pregnant or who plan to become pregnant during the study, or are breastfeeding.
  • Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
709 participants (actual)

Study arms

  • Experimental
    1

    ACT-293987, twice daily

    Drug: ACT-293987

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation

    An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.

    Time frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)

  2. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.

    Time frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)

  3. Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention

    An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.

    Time frame: Up to 10.5 years

Secondary outcomes

  1. Percentage of Alive Participants

    Percentage of alive participants were analyzed using Kaplan-Meier (KM) estimates.

    Time frame: Baseline (Day 1), Months 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

07

Results

Posted Sep 19, 2022
Limitations and caveats
The study had an open-label, uncontrolled design. Additional pulmonary arterial hypertension (PAH)-specific treatments were introduced in a limited percentage of participants and during a limited period of time. The study had a variable study duration across countries/territories depending on the availability of commercial selexipag. Limited safety data reporting was done in participants in China due to the human genetic resources (HGR) regulation finding after 20-December-2019.

Participant flow

Participant flow — Overall Study
MilestoneSelexipag
Started709
Completed424
Not completed285
Withdrew: Death175
Withdrew: Lost to follow-up9
Withdrew: Withdrawal by subject31
Withdrew: Other70

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.

Time frame:
Up to 3 days after study drug discontinuation (Up to 10.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation
ParticipantsSelexipag
Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation684
PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation

An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.

Time frame:
Up to 3 days after study drug discontinuation (Up to 10.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation
ParticipantsSelexipag
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation420
PrimaryNumber of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.

Time frame:
Up to 10.5 years
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention
ParticipantsSelexipag
Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention129
SecondaryPercentage of Alive Participants

Percentage of alive participants were analyzed using Kaplan-Meier (KM) estimates.

Time frame:
Baseline (Day 1), Months 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Number · Percentage of participants
Percentage of Alive Participants
Percentage of participantsSelexipag
KM estimate at Baseline (Day 1)100 (100 to 100)
KM estimate at Month 398.4 (97.0 to 99.2)
KM estimate at Month 696.3 (94.4 to 97.6)
KM estimate at Month 994.0 (91.7 to 95.7)
KM estimate at Month 1292.0 (89.4 to 94.0)
KM estimate at Month 2485.3 (82.0 to 88.0)
KM estimate at Month 3679.3 (75.4 to 82.6)
KM estimate at Month 4875.2 (70.9 to 78.9)
KM estimate at Month 6071.2 (66.5 to 75.3)
KM estimate at Month 7266.8 (61.6 to 71.4)
KM estimate at Month 8463.3 (57.8 to 68.3)
KM estimate at Month 9660.3 (54.4 to 65.7)
KM estimate at Month 10856.9 (50.3 to 62.9)
KM estimate at Month 12056.9 (50.3 to 62.9)

Adverse events

Collected over Up to 10.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag186/709 (26.2%)420/709 (59.2%)598/709 (84.3%)
Most frequent serious events
Showing 10 of 347
Most frequent serious events
EventSelexipag
Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders169/709
Right Ventricular FailureCardiac disorders93/709
PneumoniaInfections and infestations50/709
SyncopeNervous system disorders18/709
DyspnoeaRespiratory, thoracic and mediastinal disorders18/709
Atrial FibrillationCardiac disorders17/709
Sudden DeathGeneral disorders14/709
Cardiac ArrestCardiac disorders13/709
DiarrhoeaGastrointestinal disorders12/709
Acute Right Ventricular FailureCardiac disorders11/709
Most frequent other events
Showing 10 of 23
Most frequent other events
EventSelexipag
HeadacheNervous system disorders328/709
DiarrhoeaGastrointestinal disorders209/709
NauseaGastrointestinal disorders135/709
Pain in JawMusculoskeletal and connective tissue disorders130/709
Oedema PeripheralGeneral disorders90/709
NasopharyngitisInfections and infestations88/709
Upper Respiratory Tract InfectionInfections and infestations84/709
CoughRespiratory, thoracic and mediastinal disorders80/709
Pain in ExtremityMusculoskeletal and connective tissue disorders78/709
DyspnoeaRespiratory, thoracic and mediastinal disorders76/709

Baseline characteristics

Age, Continuous
Age, Continuous(years)Selexipag
Mean47.9 ± 15.19
Sex: Female, Male
Sex: Female, Male(Participants)Selexipag
Female590
Male119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Selexipag
ASIAN171
BLACK OR AFRICAN AMERICAN15
HISPANIC87
OTHER8
WHITE428
Region of Enrollment
Region of Enrollment(Participants)Selexipag
ARGENTINA20
AUSTRALIA37
AUSTRIA3
BELARUS34
BELGIUM17
CANADA13
CHILE31
CHINA113
COLOMBIA3
CZECH REPUBLIC11
DENMARK4
FRANCE21
GERMANY35
GREECE6
HUNGARY10
INDIA15
IRELAND4
ISRAEL11
ITALY4
MALAYSIA2
MEXICO20
NETHERLANDS4
PERU6
POLAND7
ROMANIA9
RUSSIAN FEDERATION72
SERBIA10
SINGAPORE8
SLOVAKIA1
SOUTH KOREA11
SPAIN8
SWEDEN10
SWITZERLAND2
TAIWAN11
THAILAND4
TURKEY8
UKRAINE35
UNITED KINGDOM9
UNITED STATES80
08

Study locations

157 sites
  • Mobile, Alabama, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • Torrance, California, United States
  • Newark, Delaware, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Austell, Georgia, United States
  • Carmel, Indiana, United States
  • Iowa City, Iowa, United States
  • Kansas City, Kansas, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Troy, Michigan, United States
  • Rochester, Minnesota, United States
  • Chesterfield, Missouri, United States
  • Saint Louis, Missouri, United States
  • Newark, New Jersey, United States
  • Bronx, New York, United States
  • Islandia, New York, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Bend, Oregon, United States
  • Portland, Oregon, United States
  • Doylestown, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • York, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Madison, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Corrientes, Argentina
  • Adelaide, Australia
  • Bedford Park, Australia
  • Chermside, Australia
  • Concord, Australia
  • Darlinghurst, Australia
  • Fitzroy, Australia
  • Hobart, Australia
  • Murdoch, Australia
  • New Lambton, Australia
  • Parkville, Australia
  • Graz, Austria
  • Vienna, Austria
  • Minsk, Belarus
  • Brussels, Belgium
  • Leuven, Belgium
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Winnipeg, Manitoba, Canada
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Saskatoon, Saskatchewan, Canada
  • Quebec, Canada
  • Santiago De Chile, Chile
  • Beijing, China
  • Guangzhou, China
  • Shanghai, China
  • Bogota, Colombia
  • Praha 2, Czechia
  • Arhus, Denmark
  • Copenhagen, Denmark
  • Bron Cedex, France
  • Le Kremlin-Bicetre Cedex, France
  • Lille Cedex, France
  • Toulouse Cedex 9, France
  • Berlin, Germany
  • Dresden, Germany
  • Giessen, Germany
  • Greifswald, Germany
  • Hannover, Germany
  • Heidelberg, Germany
  • Köln, Germany
  • Leipzig, Germany
  • Löwenstein, Germany
  • Regensburg, Germany
  • Alexandroupoli, Greece
  • Athens, Greece
  • Thessaloniki, Greece
  • Budapest, Hungary
  • Debrecen, Hungary
  • Pecs, Hungary
  • Szeged, Hungary

Showing the first 100 of 157 sites across 38 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Galie N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. PubMed 34727317 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2010 to primary completion in Aug 2021, 133 months.

Results were first posted in Sep 2022, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 133 months is above that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2010
First posted
Apr 28, 2010
StartActual
Jul 7, 2010
Primary completionActual
Aug 26, 2021
CompletionActual
Aug 26, 2021
Results first posted
Sep 19, 2022
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01112306
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 28, 2010
Start date
Jul 7, 2010
Primary completion
Aug 26, 2021
Completion
Aug 26, 2021
Results posted
Sep 19, 2022
Last update
Mar 30, 2025

Study contacts

Aline Frey
study director · Actelion

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion